Topic
pembrolizumab
1 stories related to this topic, newest first.
Wikimedia Commons (Public domain)world25 days ago
Study Finds Relacorilant May Extend Survival in Platinum-Resistant Ovarian Cancer Patients
A clinical trial showed that adding relacorilant to standard treatment extended median survival by 4.1 months for patients with platinum-resistant ovarian cancer. The study involved 381 participants and reported a 35 percent reduction in mortality risk. Separately, another trial…